Siavash Atrchian, MD, FRCPC

Clinical Assistant Professor, Division of Radiation Oncology and Developmental Radiotherapeutics, UBC Department of Surgery, Radiation Oncologist, BC Cancer, Kelowna, BC

Dr. Siavash Atrchian is a radiation oncologist at BC Cancer with extensive experience in the field of radiation oncology, specializing in the use of advanced radiation therapies to treat lung, GI and breast cancers, with a special interest in Stereotactic Body Radiotherapy (SABR).

Dr. Atrchian is an Assistant Professor of Radiation Oncology at University of British Columbia. He completed his medical training at Tehran University, followed by a specialized residency in radiation oncology at Dalhousie University in Halifax, Canada. He also completed his fellowship at the University of British Columbia.

His clinical practice is complemented by a robust research portfolio, including his contributions as an author or co-author to national and international studies, published in leading medical journals. He has initiated and participated in multiple ongoing research projects, focused on enhancing patient outcomes, optimizing SABR treatment, patient-centered care, and quality improvement projects.

In addition to his clinical work, Dr. Atrchian actively mentors medical students, radiation oncology residents and fellows, fostering professional development within the field.

He is also the Chair of the BC Cancer Virtual Academic Forum, the most attended virtual and weekly educational oncology meeting in British Columbia with more than 4000 attendees per year.

Dr. Atrchian is the founder and Chair of the SABR Canada Conference, the only national SABR conference focused on advancing the practice and research of Stereotactic Ablative Radiotherapy across Canada.

https://surgery.med.ubc.ca/people/s-atrchian/

Michael Darud is the COO of SABR Canada. Previously, he spent 20 years working as a Radiation Therapist so has a keen interest in the advancements in radiation treatment.

Houda Bahig, MDCM, PH.D.

Associate Professor, Department of Radiology, Radiation Oncology & Nuclear Medicine, Université de Montréal, Radiation Oncologist, CHUM, Montreal, QC

Dr Bahig specializes in the treatment of head and neck cancers and lung cancers, with a special interest for the development of pragmatic clinical trials evaluating new technological approaches to individualize radiotherapy. She also works on the development of algorithms using artificial intelligence to predict the response and side effects of head and neck, and thoracic radiotherapy.

Dr. Alanah Bergman, PhD, FCCPM

BSc McGill University, Physics (Hon), 1994
MSc McGill University, Medical Radiation Physics, 1997
PhD University of British Columbia, Physics (Medical Physics), 2007

Dr. Bergman is a senior medical physicist at BC Cancer - Vancouver and Fellow of the Canadian College of Physicists in Medicine. She provides physics leadership for many of the SABR trials and anatomical site initiations at her centre. She has contributed to protocols for some of the Canadian-led phase II/III trials and registries, including SABR-COMET-3, SIMPLIFY-SABR-COMET, SABR-5. Her interests currently lie with motion management for lung and liver SABR, re-irradiation scenarios, and clinical trials initiation.

Laura Dawson, MD, FASTRO

Professor, Department of Radiation Oncology, University of Toronto, Radiation Oncologist, PMH, Toronto, ON

Laura Dawson is Professor and Chair of the Department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist at the Radiation Medicine Program, Princess Margaret Cancer Centre, in Toronto. She is an internationally recognized leader in hepatobiliary cancer and in oligo-metastases. Her research has primarily focused on implementation of advanced radiation technologies (e.g. stereotactic body radiation therapy (SBRT) and image guided radiation therapy (IGRT)) to improve outcomes and to reduce the risk of toxicity of cancer patients. She has led phase I, II and more recently, phase III clinical trials of radiation therapy to treat patients with hepatocellular carcinoma and liver metastases. Dr. Dawson has published over 200 scientific papers and has mentored over 50 students from around the world. She has received numerous awards for her teaching, research and impact in oncology. She was the 2018 Canadian Association of Radiation Oncology (CARO) Gordon Richards lecturer, and she is the past Chair and past President of the American Society for Radiation Oncology (ASTRO).

Alex Louie, MD, PhD, MSc, FRCPC
Clinician Scientist and Radiation Oncologist, Sunnybrook Odette Cancer Centre
Associate Professor, University of Toronto
Toronto, ON

Dr. Louie is an Associate Professor, Radiation Oncologist and Clinician Scientist at Sunnybrook Health Sciences Centre, University of Toronto. During his fellowship, he obtained an MSc in Epidemiology at the Harvard School of Public Health, and a PhD from the VU University, Amsterdam. He leads the lung cancer team at Sunnybrook, and holds ASTRO and IASLC leadership and committee roles. He is a lung cancer section editor of the Red Journal and is a member of the Lancet Oncology International Advisory board.

Dr. Louie has published over 250 peer-reviewed manuscripts and his research focuses on clinical trials, comparative effectiveness, economic evaluation and technology appraisal in lung, kidney and oligometastatic cancers.

Benjamin Mou, MD, FRCPC

Radiation Oncologist, BC Cancer Kelowna
Clinical Associate Professor, University of British Columbia

Dr. Mou is a radiation oncologist at BC Cancer Kelowna and clinical associate professor at the University of British Columbia. He chairs the SABR and Lung Technical Sites Teams in Kelowna and is Past Chair of the BC Provincial Lung Radiation Oncology Group. He specializes in SABR for multiple body sites with clinical and research interests in thoracic, neurologic, and gastrointestinal malignancies. He serves as a site principal investigator for multiple international SABR clinical trials and is a provincial leader in BC Cancer’s SABR program. Dr. Mou is the SABR fellowship director in Kelowna and is the clinical lead for the provincial Lung and Spine SABR guidelines in BC.

Daniel Chang, MD FASTRO

Isadore Lampe Professor and Chair
Department of Radiation Oncology
University of Michigan
Ann Arbor, MI

Dr. Daniel Chang is currently the Isadore Lampe Professor and Chair of the University of Michigan Department of Radiation Oncology. He received his MD from Wayne State University in 2002 and completed his residency in Radiation Oncology at the University of Florida in Gainesville, Florida in 2007. He then joined the Department of Radiation Oncology at Stanford University from 2007-2022, having previously served as residency program director from 2012-2017 and the Vice Chair of Clinical Operations from 2017-2022 where he was also the Sue and Bob McCollum Professor in Radiation Oncology.
Dr. Chang is a nationally and internationally recognized expert in radiotherapy for GI malignancies. His primary research interest is in advanced radiotherapy techniques, primarily with stereotactic body radiotherapy (SBRT). He has led several studies investigating and establishing the efficacy and safety for SBRT for these diseases for liver and pancreatic tumors. His other research interests include normal tissue tolerances, quality of life after radiotherapy, and combining radiotherapy with targeted agents. In addition, he has a strong interest in the use of radiotherapy, particularly in combination with systemic agents, in patients with metastatic disease. Another area of interest is in health care utilization for patients with metastatic disease and using machine learning and other approaches to optimize care during the end-of-life period.

Drew Moghanaki, MD, MPH

Professor and Chief of Thoracic Oncology, Department of Radiation Oncology
Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research
David Geffen School of Medicine at UCLA
Staff Physician & Co-Director | VA Greater Los Angeles Lung Precision Oncology Program
UCLA Health | Jonsson Comprehensive Cancer Center
Los Angeles, CA

Dr. Drew Moghanaki (MD, MPH) is Professor and Chief of Thoracic Oncology in the UCLA Department of Radiation Oncology. He is co-director of the VA Greater Los Angeles Lung Precision Oncology Program and co-chair of the VALOR phase III randomized trial for operable stage I non-small cell lung cancer.

Professor Suresh Senan is a radiation oncologist at the Amsterdam University Medical Centers in The Netherlands. His research has focused on trials of systemic agents and radiation for lung malignancies, new radiotherapy techniques and study of population outcomes. He is a faculty member for thoracic malignancies at the European Society of Medical Oncology and the International Association for the Study of Lung Cancer. His group has previously hosted visiting Canadian radiation oncologists, and has ongoing collaborations with clinicians in Canada.

Prof. Shankar Siva PhD MBBS FRANZCR
Victorian Cancer Council Colebatch Fellow
Department of Radiation Oncology, Peter MacCallum Cancer Centre
Sir Peter MacCallum Department of Oncology, University of Melbourne
Melbourne, Australia

Dr Siva leads the Stereotactic Ablative Body Radiotherapy (SABR) program at PeterMac, treating > 450 SABR courses annually across 5 campuses. Under his leadership, the Peter Mac SABR service has become globally renowned for pioneering research in oligometastatic disease, lung and kidney cancers. Dr Siva is a dedicated clinical trialist. He has designed and co-ordinated 15 investigator-initiated clinical trials in the context of oligometastases, lung, kidney and prostate cancers, including 5 national/international TransTasman Radiation Oncology Group(TROG) multicentre trials. In total, he has over 300 peer- publications, including first or senior author publications in Lancet Oncology, Lancet Respiratory Medicine, Journal of Clinical Oncology, and JAMA Onc.

He serves in several international leadership roles, such as the Board of Directors of the Radiosurgery Society (RSS), the International Association for the Study of Lung Cancer (IASLC) Multidisciplinary Sciences committee, American Society of Clinical Oncology planning track and the American Society of Radiation Oncology (ASTRO) Science Council. His current career focuses on translating insights from the imaging and correlative specimens in his clinical trials into prognostic, predictive and actionable biomarkers. Dr Siva is scientific communicator on twitter@_ShankarSiva

Dr. Derek Hyde, PhD, FCCPM

Senior Medical Physicist, BC Cancer, Kelowna, BC
Adjunct Professor, Medical Physics, UBC - Okanagan

Dr. Hyde completed his PhD in imaging, focusing on the development of CBCT for neuroangiography. This work sparked an interest in IGRT and stereotactic techniques. Dr. Hyde was the physics lead for the team that established the first Canadian spine SABR program at Sunnybrook over 15 years ago. Since moving to Kelowna, he has continued to develop innovative strategies for SABR techniques as the physics lead and co-chair of the SABR group. He has contributed to provincial SABR protocols as well as the SABR-5 phase 2 clinical trial. His research interests include lung radiotherapy, radiomics, SRS, SABR, SFRT (Lattice), Adaptive Radiosurgery and 3D Gel Dosimetry.

Mitchell C.C. Liu, MDCM, FRCPC

Clinical Professor of Radiation Oncology,
Department of Surgery,
University of British Columbia,
Vancouver, BC

Mitchell C.C. Liu, MDCM, FRCPC is a Clinical Professor of Radiation Oncology in the Department of Surgery, University of British Columbia. Dr. Liu completed his radiation oncology residency at McGill University and a radiation oncology fellowship at Massachusetts General Hospital. He practices at the BC Cancer, Vancouver Centre and he is the Lung Cancer Site Team Lead at Vancouver. Dr. Liu is one of the leaders at BC Cancer for SABR (Lung, Liver, Spine, and Oligometastases) and involved in multiple SABR trials, Provincial SABR and OAR constraints guidelines. He is an author on more than 200 publications.

Andrew Loblaw, BSc MD MSc FRCPC CIP FASCO

Radiation Oncologist, Clinician Scientist, Dual Professor,
Department of Radiation Oncology,
Institute of Health Policy Management & Evaluation
University of Toronto,
Toronto, ON

Dr Andrew Loblaw is a Radiation Oncologist, Clinician Scientist, and dual Professor in the Department of Radiation Oncology and the Institute of Health Policy Management & Evaluation at the University of Toronto. He’s the Site Group Co-Lead for Genitourinary Oncology at Sunnybrook.

He received a Bachelor of Science in Physics from the University of British Columbia and his Doctor of Medicine from Queen’s University. He completed his specialty training in Radiation Oncology concurrent with a Masters degree in Clinical Epidemiology to graduate from the Royal College’s Clinician Investigator Program all at the University of Toronto.

Dr Loblaw’s clinical practice and research interest focus on improving outcomes for men with prostate cancer and the healthcare system. He has a particularly interest in the design and conduct of clinical trials, the generation and dissemination of evidence-based guidelines and in image-guided radiotherapy.

Dr Loblaw is an Ontario Association of Radiation Oncology Clinician Scientist and a Senior Scientist at the Sunnybrook Research Institute. A Fellow of the American Society of Clinical Oncology (FASCO), he was previous Co-Chair of the ASCO’s Genitourinary Advisory Group and remains Co-Chair of the GU group for Cancer Care Ontario’s Program in Evidence-Based Care. He has authored over 300 peer-reviewed papers and has been awarded grant funding of over Cdn$52M.

Anand Swaminath MD FRCP(C)

Associate Professor, Department of Oncology, McMaster University
Scientist, Escarpment Cancer Research Institute
OARO Clinician Scientist and Radiation Oncologist
Juravinski Cancer Centre
Hamilton, ON

Dr. Swaminath is an Associate Professor, Clinician Scientist and Radiation Oncologist at the Juravinski Cancer Centre, McMaster University, Hamilton.
He received his medical degree from the University of Ottawa, finished residency training at McMaster University, and completed a clinical-research fellowship in image-guided radiotherapy/SBRT for lung and liver cancer at the Princess Margaret Cancer Centre.

His clinical and research interests are in the application of new technologies in radiation therapy, specifically SBRT for a wide variety of indications including lung, kidney, and liver cancer, both for symptom control and in the management of metastatic disease.

Dr. Swaminath is a PI or radiation lead on several local, national, and international trials evaluating SBRT in both the primary and metastatic setting. Some trial highlights include the lead on the Canadian LUSTRE randomized lung SBRT trial, and radiation lead on the CYTOSHRINK and RADSTER trials in kidney cancer, and ADVANCE trial for HCC. He has authored or co-authored more than 80 peer reviewed publications and book chapters, and has obtained several large-scale grants through CIHR and CCSRI for trials that both locally and nationally involve the evaluation of SBRT in the primary and metastatic setting.

Sarah Baker, MD

Assistant Professor,
University of British Columbia
Radiation Oncologist,
BC Cancer,
Surrey, BC

Dr. Sarah Baker is an Assistant Professor at the University of British Columbia and a radiation oncologist at BC Cancer Surrey, where she has worked since 2018. She received her MD from the University of British Columbia and completed residency training at the Cross Cancer Institute in Edmonton (University of Alberta). She completed a fellowship and PhD in stereotactic radiotherapy for lung and head and neck malignancies at Erasmus MC in Rotterdam, the Netherlands. Her clinical and research interests include the treatment of lung malignancies and oligometastases, with a focus on SABR and advanced radiotherapy technologies. Dr. Baker is the medical director of the Clinical Trials Unit at BC Cancer Surrey. She is the principal investigator of the upcoming international randomized clinical trial evaluating the potential benefit of precision radiotherapy for oligoprogressive cancer (“The STOP-2 Trial”).

Dr. Melanie Davidson is an adjunct professor in the department of Computer Science, Mathematics, Physics and Statistics at University of British Columbia Okanagan, and has been working as a Medical Physicist at BC Cancer Kelowna since October 2023. Melanie completed her Ph.D. in Medical Biophysics with a focus in x-ray imaging at Western University followed by a residency in Medical Physics at the London Regional Cancer Program, in London Ontario. She worked at the Odette Cancer Centre (OCC), Sunnybrook Health Sciences centre in Toronto, Ontario from 2008-2023, where she led the technical development of various prostate SABR clinical trials. Dr. Davidson is currently the radiation therapy quality assurance physicist for Canadian Cancer Trials Group (CCTG) trials related to the use of SABR in prostate cancers (including PR.24, and the recently completed PR20). Her current research interests are focused on the use of adaptive radiotherapy and brachytherapy for GU and Gynae.

Emma Dunne

Clinical Assistant Professor of Radiation Oncology,
Department of Surgery,
University of British Columbia,
Vancouver, Canada

Dr. Emma Dunne is a Clinical Assistant Professor of Radiation Oncology in the Department of Surgery, University of British Columbia, Vancouver, Canada since 2022. Dr. Dunne received her undergraduate education at University College Dublin, Ireland studying Molecular Genetics, prior to completing a PhD at the University of Bristol in the UK. She studied medicine at Barts and The Royal London Hospital, London, UK and completed her specialist Clinical Oncology training at The Royal Marsden Hospital. On completion of training Dr. Dunne proceeded to a 2-year Precision Fellowship at BC Cancer, Vancouver from 2017 - 2019 where she specialized in treating metastatic disease to the spine and liver with SBRT. Dr Dunne is a member of the Lung, GI and SBRT groups. Her research interests include SBRT specifically in the setting of primary and secondary liver malignancies, metastatic disease to the spine and pelvic re-irradiation.

Dr. Angela Lin

Radiation Oncologist, BC Cancer, Kelowna BC

Dr. Angela Lin completed medical school at University of BC, residency at McMaster University, and fellowship at University of Toronto. She is a Radiation Oncologist at BC Cancer Kelowna and a Clinical Assistant Professor in the Faculty of Medicine at UBC. She is the principal investigator and co-principal investigator of several current research studies. She is the co-chair of the Interior BC Breast Tumour Group. She is an active member of the BC Cancer’s Stereotactic Ablative Body Radiotherapy program.

Islam G Mohamed, MD FRCPC

Radiation Oncologist, BC Cancer—Kelowna

Dr Mohamed earned a Bachelor’s degree in Genetics before obtaining his degree in Medicine at the University of Alberta, and completing a residency in Radiation Oncology at the Cross Cancer Institute. He began his oncology practice at BC Cancer in 2000. His current practice includes lung, sarcoma, and skin tumour sites, with a special interest in stereotactic radiosurgery. His research focuses on stereotactic radiosurgery for lung cancer and oligometastatic disease.

Robert Olson, MD, FRCPC, MSc

Rob Olson is a Radiation Oncologist and researcher who practices in BC Cancer - Prince George, where he is also the Executive Medical Director. He is also the Division Head of Radiation Oncology and UBC. His primary research focus is on SABR in the setting of metastatic disease, and is the principal investigator on several SABR clinical trials, including SABR-5 and SABR-COMET-3.

Amir Safavi, MD, MSc, FRCPC

Clinical Fellow, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

Dr. Amir Safavi is a Radiation Oncologist and Advanced Clinical Radiation Oncology Fellow at Memorial Sloan Kettering Cancer Center. He completed residency training at Princess Margaret Cancer Centre and Sunnybrook Odette Cancer Centre. Dr. Safavi holds degrees from Columbia University and the University of Toronto.

Dr. Safavi’s interests relate to his clinical training in head and neck cancer, lung cancer, and oligometastatic disease, and technical training in stereotactic (SBRT and SRS), adaptive (MR- and CT-based), and proton radiotherapy. He aims to evaluate the clinical effectiveness and health system impacts of cancer care interventions and discover novel strategies (molecular, radiomic, and technology-based) for improving the therapeutic index of radiotherapy.

Dr. Safavi (@safaviaa) is active in the #radonc community on X/Twitter.

Devin Schellenberg, BSc MD FRCPC

Clinical Associate Professor - UBC
Department Head, Radiation Oncology
BC Cancer - Surrey Centre

Dr. Devin Schellenberg completed medical school and Residency at the University of BC and University of Toronto. He went onto a Fellowship at Stanford University and has been the Department Head of Radiation Oncology at the BC Cancer Surrey Centre for the past 4 years. He chairs the Lung Radiation Oncology working group with CCTG and is a founding member of CAPRI (Canadian Pulmonary Radiotherapy Investigators Group).

He has been a leader in BC Cancer’s Stereotactic Ablative Body Radiotherapy (SABR) programs and his current research efforts focus on how radiation can alter the course of metastatic disease and (outside of cancer) whether radiation is able to treat heart arrhythmias.